Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NAFLD - Nonalcoholic Fatty Liver Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

Spironolactone Therapy In Young Women With NASH

NCT03576755
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Spironolactone 100mg, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 13, 2026, 9:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

NCT02083367
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

NCT04874233
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HU6, Placebo
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
28 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04321343
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
PXL065, Placebo oral tablet
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
29
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 13, 2026, 9:15 PM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology

NCT03294941
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HepQuant SHUNT Liver Diagnostic Kit
Combination Product
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Dallas, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated No phase listed Observational

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

NCT00283374
View directory record Official record
Conditions
Morbid Obesity, Metabolic Disease
Interventions
Laparoscopic Roux-en-Y Gastric Bypass
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Irvine, California • Orange, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

NCT06195943
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, NASH, Exercise, Liver
Interventions
Exercise Intervention with use of El-Fit App
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 13, 2026, 9:15 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

NCT04501406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

Tocotrienol Against the Progression of End Stage Liver Disease

NCT02581085
View directory record Official record
Conditions
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Tocotrienol (TCT), Placebo
Drug · Other
Lead sponsor
Chandan Sen
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

NCT04634149
View directory record Official record
Conditions
Moderate Liver Impairment, Severe Liver Impairment
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03551522
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Seladelpar, Placebos
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Glendale, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Early Phase 1 Interventional Results available

Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents

NCT02726542
View directory record Official record
Conditions
NAFLD
Interventions
somatropin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT02854605
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
GS-9674, Placebo to match GS-9674
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of HU6 in Healthy Volunteers

NCT04463017
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults

NCT03142867
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Interventions
non-applicable
Other
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
826 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

NCT04173065
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
VK2809, Placebos
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
68
States / cities
Madison, Alabama • Glendale, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 13, 2026, 9:15 PM EDT
Recruiting Phase 2 Interventional

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

NCT05526144
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
El Cajon, California • Murrieta, California • Rialto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NCT00845845
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis
Interventions
Omega-3-acid ethyl esters (Lovaza), Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

NCT03610945
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Fluconazole, Quinidine, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 13, 2026, 9:15 PM EDT
Not listed No phase listed Observational

Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

NCT02124577
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 13, 2026, 9:15 PM EDT